A five-year forecast of assisted reproductive technology, in vitro fertilization, and third-party reproduction, covering market sizing, competitive structure, policy trajectory, and demand shifts through 2031.
The assisted reproductive technology (ART) sector enters 2026 in a rare position: structurally supply-constrained, demographically underwritten for decades, and, for the first time in its history, the object of active federal policy support in the United States. Mordor Intelligence sizes the global in vitro fertilization market at $30.90 billion in 2026, projecting $45.90 billion by 2031 at an 8.28% CAGR across precisely this forecast window. Broader ART definitions that fold in laboratory consumables, media, genetic testing, and clinical services produce a wider 2026 band: Persistence Market Research puts the sector at $31.2 billion, Grand View Research at $33.4 billion, Coherent Market Insights at $35.7 billion, Global Market Insights at $41.4 billion, and Business Research Insights at $51.3 billion. Published CAGRs cluster between 5% and 9%, with several outliers above 20% that reflect scope inflation rather than a different read on demand.
The verdict for 2026 to 2031 is strong growth, with the caveat that growth is unevenly distributed and politically exposed. Demand is not the constraint. The World Health Organization estimates roughly 17.5% of adults, about one in six people, experience infertility. In 2024, SART-member clinics reported 449,772 IVF treatment cycles in the United States and, for the first time, more than 100,000 babies born through IVF in a single year. CDC surveillance recorded 435,426 ART cycles in 2022 producing 98,289 live-born infants, about 2.6% of all US births. The binding constraints are affordability, a severe shortage of reproductive endocrinologists and embryologists, and legal uncertainty around embryo status.
Three forces will define the window. First, coverage expansion: California's SB 729 took effect January 1, 2026, requiring fully insured large-group plans to cover up to three egg retrievals and unlimited embryo transfers, reaching an estimated nine million enrollees, while a federal proposed rule published May 13, 2026 would create a new excepted-benefit category letting employers offer fertility benefits directly, with a $120,000 indexed lifetime cap, effective January 1, 2027. Second, consolidation and capital rotation: private-equity-affiliated clinics grew from 4% of US fertility clinics in 2013 to 32% in 2023 and performed 52% of all 2022 US IVF cycles, and most sponsoring funds are now at end-of-life and seeking exits. Third, technology compression: AI embryo selection, laboratory robotics, and electronic witnessing are shortening time-to-live-birth and standardizing outcomes, which raises volume per patient-year even where patient counts stay flat.
Third-party reproduction, the sub-segment covering gestational surrogacy and egg donation, is the sector's highest-growth and highest-variance slice. Market sizing here is genuinely unreliable because firms disagree on whether to count agency fees alone or total journey value. IMARC sizes global surrogacy at $204.6 million in 2025 (agency-fee scope), The Insight Partners at $5.38 billion, and Mordor Intelligence at $28.91 billion in 2026, rising to $78.68 billion by 2031 (full-journey scope). Readers should treat the growth direction as well evidenced and the absolute level as unsettled.
Assisted reproductive technology covers all fertility treatments in which eggs or embryos are handled outside the body. The operative sub-segments are:
This report treats the United States as the anchor market and the third-party reproduction segment as the analytical centre of gravity, with global and regional comparisons where they materially change the picture.
Published 2026 estimates for the global ART market span roughly $31 billion to $51 billion, a spread driven almost entirely by scope rather than by disagreement about underlying demand. Narrow definitions count laboratory products and procedures; broad ones include the full clinical services revenue line. For a single defensible anchor, Mordor Intelligence places IVF specifically at $30.90 billion in 2026 against $28.55 billion in 2025.
Grand View Research sizes the wider fertility services market, which layers clinical delivery on top of ART products, at $52.7 billion for 2026, growing to $70.3 billion by 2030 at 7.5%. Europe held the largest regional share of fertility services at roughly 36% as of the most recent Grand View breakdown, while North America is generally identified as the fastest-growing major region on a revenue basis and Asia-Pacific the fastest on volume.
Segment composition is stable and informative. Fertility clinics, not hospitals, are the dominant provider channel, holding roughly 80% of fertility services revenue per Grand View Research. Frozen non-donor cycles dominate procedure mix: CDC data show 86.9% of 2022 US ART cycles used frozen embryos, and 184,423 of the 435,426 cycles reported that year were egg or embryo banking cycles in which everything retrieved was frozen for later use. That last figure matters commercially, because banking cycles decouple revenue timing from birth outcomes and create recurring storage income.
[IMAGE SUGGESTION: Column chart of global IVF market size 2026 vs 2031 ($30.9B to $45.9B), with a shaded band showing the wider $31B-$51B ART scope range for 2026. Source: Section 2b figures, Mordor Intelligence and comparators.]
Demand for ART rests on demographic changes that are slow, well documented, and effectively irreversible within the forecast window.
The ART value chain runs from upstream product suppliers through clinical delivery to third-party coordination, with benefits managers increasingly controlling patient routing.
Upstream, a small group of manufacturers (CooperSurgical, Vitrolife, Merck KGaA, Thermo Fisher Scientific, Hamilton Thorne) supply media, incubators, and instruments at high gross margin with meaningful switching costs, because a laboratory that has validated protocols on one media system does not casually change it. Vitrolife's EmbryoScope time-lapse incubator, priced by Mordor Intelligence at $80,000 to $120,000, anchors the premium tier.
Midstream, clinical delivery has consolidated into national platforms. Inception Fertility, US Fertility, Pinnacle Fertility, IVI RMA, and Kindbody each operate multi-state networks with centralized operations and standardized technology stacks. Economics are cycle-driven, with revenue per cycle in the roughly $15,000 to $23,000 range for IVF before medications, per figures cited by Maven Clinic and Mordor Intelligence.
Downstream, third-party reproduction operates on a fundamentally different model. Surrogacy agencies coordinate rather than deliver clinical care: they recruit and screen gestational carriers, match them to intended parents, and manage legal, escrow, insurance, and case-management workflows across an 11-to-24-month journey. A full US gestational surrogacy program runs approximately $150,000 to $220,000 in 2026 per Egg Donor & Surrogacy Institute analysis, with surrogate base compensation commonly starting near $60,000 and total surrogate packages reaching $80,000 to $110,000 or more. Agency fees are a modest fraction of that total, which is why agency-scope and journey-scope market sizing diverge by two orders of magnitude.
Benefits managers (Progyny, Carrot Fertility, Maven Clinic, Kindbody, WIN Fertility) sit alongside this chain and increasingly determine where patients go. Progyny's cycle-based Smart Cycle design explicitly prices a surrogacy IVF cycle at 1.5 cycles and a reciprocal IVF cycle at 1.25, and in September 2025 Cigna announced a collaboration extending Progyny's benefit, including surrogacy and adoption support, to most of its self-funded employer clients.
The sector faces real friction. Severity below reflects the potential to constrain sector revenue over the 2026 to 2031 window.
| Headwind | Description | Severity |
| Affordability ceiling | US IVF runs roughly $15,000-$23,000 per cycle before drugs; surrogacy runs $150,000-$220,000. Maven reports 45% of employees have delayed other financial priorities and 28% incurred debt for healthcare costs. Most of the addressable population still cannot self-pay. | High |
| Clinical workforce shortage | Only about 1,500 board-certified reproductive endocrinologists practice in the US, with roughly 40-50 fellows graduating annually, insufficient to replace retirements. Embryologist supply is a parallel bottleneck with few training programs. Capacity, not demand, caps cycle growth. | High |
| Embryo personhood litigation | The 2024 Alabama LePage ruling classified frozen embryos as "extrauterine children," halting IVF at three clinics until a shield law passed. Fetal personhood bills were introduced in at least 14 state legislatures in 2024. Shield statutes sit below state constitutional provisions. | High |
| Surrogacy excluded from mandates | SB 729 and most state IVF mandates cover the intended parent's treatment, not gestational carrier compensation, escrow, or agency fees. The largest cost block in a surrogacy journey remains almost entirely self-pay. | High |
| Cross-border jurisdictional volatility | Russia banned surrogacy for foreigners in 2022, Georgia drafted a foreigner ban in 2024, Argentina saw clinic raids and a court reversal in 2024, Greece imposed a residency rule in 2025, and the Hague Conference suspended its parentage and surrogacy convention project in March 2026. No global legal standard is forthcoming. | Medium |
| Referral-channel disintermediation | As PE-affiliated networks internalize ancillary services including egg donation banks and surrogacy agencies, independent agencies lose the clinic-referral pipeline that historically supplied their intended-parent flow. | Medium |
| Low-cost destination competition | Mexico and Colombia programs are marketed at roughly $49,000-$90,000 against US programs starting near $100,000, drawing cost-sensitive intended parents despite weaker legal recognition. | Medium |
| Ethical and reputational scrutiny | Commercialization critiques, PE ownership disclosure concerns, and debates over surrogate compensation create ongoing narrative risk and potential for state-level restriction. | Medium |
The sector has no single dominant firm. Leadership is segmented: product manufacturers, clinical networks, benefits managers, and third-party coordinators each have their own leaders with limited overlap.
| Company / HQ | Market Position | Core Offering | Competitive Moat | Recent Moves | Growth Trajectory |
| CooperSurgical (Trumbull, CT, USA) | Leading ART products supplier; named by Global Market Insights among the top five ART players | Culture media, consumables, genetic testing, laboratory equipment | Protocol lock-in: labs validated on a media system rarely switch; breadth across the lab workflow | Continued build-out of integrated genomics and consumables portfolio serving expanding clinic networks | Steady, tracking cycle volume |
| Vitrolife AB (Gothenburg, Sweden) | Premium laboratory technology leader | Time-lapse incubation (EmbryoScope), media, AI-assisted embryo evaluation | Installed base plus data: time-lapse systems generate the imaging datasets that train embryo-selection algorithms | Strategic expansion into genomic services; iDAScore AI platform adoption in FDA-cleared embryo selection | Strong, tied to AI adoption |
| Merck KGaA / EMD Serono (Darmstadt, Germany) | Leading fertility pharmaceuticals supplier | Gonadotropins and ovarian stimulation drugs (Gonal-f, Ovidrel, Cetrotide) | Regulatory approvals, manufacturing scale, and clinical familiarity in stimulation protocols | October 2025 agreement with the White House delivering an 84% discount off list on a typical IVF medication set, distributed via TrumpRx.gov from January 2026 | Volume up, price per unit down |
| IVI RMA Global (Valencia, Spain; KKR-backed) | Largest global reproductive medicine group by footprint | Full-service fertility clinics across 15+ countries | Global scale, academic affiliations (Boston IVF links to Harvard, Tufts, Dartmouth), proprietary outcomes data | Acquired Eugin Group North American operations including Boston IVF and TRIO for roughly $535M, closed January 2024; reported pursuit of ART Fertility Clinics at roughly $400-450M | Aggressive, acquisition-led |
| US Fertility (Rockville, MD, USA) | Largest pure-play US fertility platform by clinic count and cycle volume | Multi-state clinic network with centralized operations | Density in high-mandate states; scale in payer contracting | L Catterton co-investment alongside Amulet Capital in December 2025; sale process reported by ION Analytics to be in a second bidding round | Growth plus ownership transition |
| Inception Fertility / Prelude Network (Houston, TX, USA) | Largest US fertility platform by revenue, reported above $500M | Clinic network plus fertility preservation and pharmacy services (inspireRx) | Vertical integration from preservation through treatment and medication access | Acquired Sincera Reproductive Medicine (2023) and Reproductive Science Center of New Jersey (2024); cited among networks preparing for sponsor exit | Consolidating, exit-stage |
| Progyny (New York, NY, USA; NASDAQ: PGNY) | Dominant US fertility benefits manager | Employer-sponsored cycle-based fertility benefit with surrogacy and adoption reimbursement | Employer contracts and a network of over 650 fertility clinics; controls patient routing without owning clinics | September 2025 collaboration with Cigna Healthcare extending the benefit to most Cigna self-funded employer clients from fall 2025 | Strong, policy-tailwind exposed |
| Circle Surrogacy (Boston, MA, USA) | Best-known national full-service surrogacy agency | Gestational surrogacy and egg donation coordination for domestic and international intended parents | Three-decade track record, fixed-fee transparency, LGBTQ+ specialization, international parent base spanning 70+ countries | Publishes an all-inclusive program at $189,500 covering agency services, surrogate compensation, legal work, and key insurance components | Steady, brand-led |
[IMAGE SUGGESTION: Competitive positioning matrix plotting the eight leaders on two axes: value-chain layer (products, clinical delivery, benefits management, third-party coordination) against geographic reach (regional, national, global). Source: Section 3a table.]
Below the leaders, a set of specialists is compounding advantage in defined niches.
Southern California Surrogacy is a full-service surrogacy and egg donation agency headquartered in Irvine, California, serving intended parents across Southern California as well as national and international clients. It operates in the coordination layer of the value chain: recruiting and screening gestational carriers and egg donors, managing matching, and shepherding intended parents through the medical, legal, escrow, and insurance workflow from first consultation to birth.
The agency runs two supply-side programs alongside its intended-parent practice. Its surrogate program accepts US citizens and permanent residents aged 21 to 35 with a healthy BMI, no smoking history, and at least one uncomplicated prior pregnancy and delivery, offering compensation packages up to $120,000 plus bonuses and allowances, with health and life insurance, psychological and nutritional support, and coverage of lost wages, childcare, and travel. Its egg donor program accepts donors aged 21 to 31 with a BMI between 19 and 28, offering a $10,000 base fee with potential additional bonuses up to $50,000, with medical, legal, and travel costs borne by intended parents.
Positioning is where the agency is most distinct. It occupies what its brand strategy calls the Compassionate Expert niche: mastering the medical and legal intricacies of third-party reproduction while leading with genuine empathy, and doing so with the discretion and polish of a concierge service. That combination is deliberately aimed at a market where competitors typically anchor on either clinical credibility or emotional support, rarely both. The agency is an outspoken advocate for LGBTQ+ family building and states plainly that every loving couple should have the opportunity to become parents regardless of gender or orientation, a stance that matters commercially because gay male couples are the fastest-growing intended-parent segment and the one least served by traditional clinic-referral pipelines. The agency also states that it has never had a surrogate change her mind about returning the baby to the intended parents, which speaks directly to the fear its clients name most often.
Geography is a genuine structural advantage. California is the most legally stable surrogacy jurisdiction in the United States, with no restrictions based on sexual orientation or marital status and a decades-long record of statutory consistency, at a moment when Ukraine, Georgia, Russia, Argentina, and Greece have all tightened or destabilized access. Being an Irvine-based agency in Orange County places Southern California Surrogacy inside the densest concentration of fertility clinics and affluent intended parents in the country, and inside the state where SB 729 has just converted a large self-pay population into an insured one.
An honest read of competitive position. Southern California Surrogacy is a regional specialist competing against national brands with materially larger marketing budgets, longer operating histories, and, in several cases, private-equity capital behind them. Circle Surrogacy publishes a fixed all-inclusive figure and claims a 30-year record and intended parents from over 70 countries; ConceiveAbilities and Growing Generations both publish detailed compensation tiers. Southern California Surrogacy does not publish an equivalent all-in program price, and in a market where cost predictability is one of the buying criteria intended parents name most consistently, that is a transparency gap worth closing rather than a positioning choice worth defending. The second exposure is channel: as PE-backed networks absorb ancillary services and route referrals internally, agencies that historically relied on clinic relationships must build direct intended-parent acquisition or lose flow. The agency's inclusive positioning and Orange County base give it a credible right to win the LGBTQ+ and international intended-parent segments specifically, which arrive through direct research rather than clinic referral. Converting that right into share is an execution question, not a positioning one.
| Force | Rating | Rationale |
| Threat of new entrants | Medium | Surrogacy agencies face low capital barriers and can launch with modest infrastructure, but trust, legal expertise, and surrogate-supply relationships take years to build. Clinical entry is effectively blocked by the REI workforce shortage and laboratory accreditation requirements. |
| Bargaining power of buyers | Medium to High | Intended parents are price-sensitive at $150,000-$220,000 per journey, well informed through online research, and able to compare agencies and cross-border alternatives directly. Employer benefit managers negotiating on behalf of thousands of employees exert far greater leverage than individuals. |
| Bargaining power of suppliers | High | Reproductive endocrinologists and embryologists are the scarce input and command rising wages. Gestational carriers hold real leverage where demand is strong, with compensation rising roughly 36% over five years per industry compilations. Premium laboratory equipment suppliers face little substitution. |
| Threat of substitutes | Low to Medium | For medically infertile patients and gay male couples, there is no clinical substitute for ART. Adoption and low-cost international destinations are partial substitutes constrained by wait times and legal recognition risk. In vitro gametogenesis is a long-horizon substitute, not a 2031 one. |
| Competitive rivalry | High | The US fertility sector is fragmented, with roughly 75% of clinics historically accounting for under 0.24% of total cycles each, while PE roll-ups compete aggressively for the remainder. Surrogacy agencies compete on compensation packages, match speed, and transparency, all of which are publicly visible and easily benchmarked. |
The scenarios below are constructed on a $40 billion global ART base for 2026, the approximate midpoint of the credible published range of $31 billion to $51 billion. These are reasoned projections built on published CAGRs, not themselves published figures, and should be read as such.
| Scenario | 2031 Market Size | Implied CAGR | Key Assumption |
| Bull | ~$70 billion | 11.8% | The federal excepted-benefit rule finalizes and takes effect January 1, 2027 as drafted, employer adoption accelerates past the current 40% baseline, additional states replicate SB 729, AI embryo selection materially lifts live-birth rates per cycle, and Asia-Pacific volume growth compounds at the double-digit country rates projected for India, China, and Japan. |
| Base | ~$60 billion | 8.4% | Published consensus holds. Coverage expands steadily but unevenly, workforce constraints cap cycle growth in the US, technology improves efficiency without a step-change in outcomes, and consolidation proceeds without disrupting delivery. This tracks closely to Mordor's 8.28% IVF CAGR and the 7.6%-8.9% cluster from Global Market Insights and The Business Research Company. |
| Bear | ~$52 billion | 5.4% | The federal rule stalls in rulemaking or litigation, embryo personhood provisions spread to additional states creating provider liability chill, affordability caps self-pay volume as it already has in surrogacy, and the private-equity exit cycle repricing depresses reinvestment in capacity expansion. |
[IMAGE SUGGESTION: Grouped column chart comparing bull, base, and bear global ART market size at 2031 ($70B / $60B / $52B) against the $40B 2026 base. Source: Section 4a table.]
Four shifts will reshape sector structure regardless of which scenario obtains.
| Technology | Description and Current State | Horizon |
| AI embryo selection | Deep-learning models score embryo viability from time-lapse imaging. FDA-cleared platforms including iDAScore reduce embryo-selection time with pregnancy rates comparable to manual grading, per Mordor Intelligence. Identified by CAS as one of the two fastest-growing innovation areas in ART between 2022 and 2024. | Deploying now; mainstream by 2028 |
| Laboratory automation and robotics | Robotic handling, automated cryogenic specimen management, and electronic witnessing. TMRW Life Sciences systems reportedly manage roughly 25% of US specimen loads. ASRM has issued committee guidance on misidentification risk points requiring robust witnessing. | Deploying now; risk-driven adoption |
| Preimplantation genetic testing | PGT-A and PGT-M screening for chromosomal and monogenic conditions, with faster turnaround. Future Market Insights projects that 40% of premium cycles will include PGT by 2026. Industry sources report 70-80% live birth rates for PGT-tested embryos in surrogacy contexts. | Mature and expanding |
| Microfluidics and lab-on-a-chip | Miniaturized environments handling sperm sorting, fertilization, and embryo culture, aimed at lowering per-cycle cost and improving consistency. | Early commercial; 2028-2031 impact |
| In vitro gametogenesis (IVG) | Creating functional gametes from somatic cells such as skin or blood. Demonstrated in mice, progressing in human research. Identified by CAS alongside AI as the fastest-growing novel method. ASRM characterizes it as a potentially transformative but currently experimental frontier. | Beyond 2031 for clinical use |
| Personalized stimulation protocols | Algorithmic and genetic tailoring of ovarian stimulation, replacing standardized dosing to improve oocyte yield and reduce cycle cancellations. | Deploying now |
| Sub-Segment | Outlook to 2031 | Basis |
| Gestational surrogacy | Very high | Published CAGRs range from 9.3% (The Insight Partners, 2026-2034) to 22.19% (Mordor Intelligence, 2026-2031). Cross-border arrangements are forecast by Mordor to grow faster than domestic at 23.71%. Wide variance reflects scope disagreement, not directional doubt. |
| Egg freezing and embryo banking | High | The Business Research Company projects $8.07 billion by 2030 at 12.3%. Mordor projects the under-35 cohort growing at 20.5% CAGR through 2030 as employer sponsorship pulls the decision earlier. |
| IVF consumables and disposables | High | Mordor projects a 10.21% CAGR to 2031, the fastest product category, as clinics shift to single-use devices under tighter sterility requirements. |
| Fertility benefits management | High | Utilization of employer fertility benefits is projected to rise to 6.8% of employees within five years from 3.2% today, per McGuireWoods, more than doubling the served base independent of any pricing change. |
| Core IVF services | Moderate to high | Mordor projects 8.28% globally to 2031. US growth is capped by REI and embryologist supply rather than demand. |
| Donor egg and third-party gametes | Moderate to high | Rises with surrogacy and with single and same-sex intended parents. Constrained by donor recruitment economics and screening throughput. |
| ART capital equipment | Moderate | Grows with clinic count and refresh cycles rather than patient volume; sensitive to the consolidation pause and PE exit timing. |
[IMAGE SUGGESTION: Horizontal bar chart of projected CAGR by sub-segment, showing gestational surrogacy, egg freezing, consumables, benefits management, and core IVF, with error bars where published estimates conflict. Source: Section 4d table.]
US federal policy has shifted from silence to active support. Executive Order 14216, "Expanding Access to In Vitro Fertilization," was issued February 18, 2025, directing agencies to identify ways to protect IVF access and reduce out-of-pocket costs. On October 16, 2025, the administration announced its first major follow-up, including the EMD Serono pricing agreement. TrumpRx.gov launched February 5, 2026. Then on May 10, 2026, the Departments of Labor, Health and Human Services, and Treasury jointly announced a proposed rule creating a new category of limited excepted benefits permitting employers to offer fertility benefits directly to employees. The Notice of Proposed Rulemaking was published in the Federal Register on May 13, 2026, with comments open through July 13, 2026 and an effective date as drafted of January 1, 2027. It would set a combined lifetime maximum of $120,000 per participant and beneficiary, indexed for inflation.
KFF's analysis is a useful counterweight: the impact will be limited to employees whose employers opt in and to patients who can afford the costs not covered by discounted drug pricing. Congressional action would be required to require or subsidize coverage broadly, and the Health Coverage for IVF Act of 2025 has seen no movement.
At the state level, approximately 19 states mandate some IVF coverage. California's SB 729, authored by Senator Caroline Menjivar and signed in 2024, was delayed from July 1, 2025 to January 1, 2026 by AB 116 and now applies to fully insured large-group plans covering 101 or more employees, mandating up to three completed egg retrievals and unlimited embryo transfers plus medically necessary fertility preservation, with CalPERS coverage following in 2027. Critically for third-party reproduction, it does not apply to self-funded plans and does not cover gestational carrier compensation.
The countervailing risk is embryo personhood. Alabama's LePage decision remains formally intact even after the state's shield law, and Alabama's constitutional provision on protecting the rights of the unborn sits above that statute. Fetal personhood bills were introduced in at least 14 legislatures in 2024, and Stateline reported in May 2026 that lawsuits challenging embryo disposal are again testing IVF exposure. Providers should assume this risk is dormant rather than resolved.
Internationally, the direction is toward fragmentation. The Hague Conference on Private International Law suspended its parentage and surrogacy convention project in March 2026 after more than a decade of work, meaning no global standard for cross-border parentage recognition is on the horizon. This is, on balance, favorable to US agencies in stable states, because legal certainty becomes the differentiating product.
North America leads on revenue and legal stability. Mordor puts North America at 40.78% of the surrogacy market in 2025, and IMARC at 41.2%, anchored by the permissive US legal environment and mature agency ecosystem. Within the US, California, Nevada, Oregon, Washington, Illinois, Connecticut, Delaware, Massachusetts, New Hampshire, and Rhode Island offer the strongest protections, including pre-birth orders. California is the deepest single market, combining legal stability with the SB 729 coverage expansion.
Europe holds the largest fertility services revenue share at roughly 36% per Grand View Research, but its surrogacy market is structurally suppressed. France, Spain, Italy, and Germany restrict or prohibit surrogacy, which converts European demand into outbound cross-border demand aimed at the US, Canada, and Latin America.
Asia-Pacific is the volume engine. Grand View's Horizon databook has Asia-Pacific at 34.2% of the global ART market and projects it to lead globally by 2030. Future Market Insights projects country-level IVF growth at 11.3% for India, 10.5% for China, and 9.1% for Japan through 2036, driven respectively by clinic proliferation and the ART Act 2021 regulatory framework, relaxation of family planning policy, and insurance coverage expansion.
Latin America is the growth story in cross-border surrogacy specifically. Mexico and Colombia accept same-sex couples and price full programs at roughly $49,000 to $90,000, materially below US levels. Colombia is not a pre-birth-order jurisdiction, so parentage steps occur after birth and families remain in-country during processing, a real friction that partially offsets the cost advantage.
[IMAGE SUGGESTION: World map or regional bar chart showing share of global ART revenue alongside projected CAGR by region, highlighting North America (revenue leader, ~41% of surrogacy), Europe (~36% fertility services), and Asia-Pacific (~34% ART, fastest growth). Source: Section 4f figures.]
| Risk | Probability | Impact | Mitigation and Notes |
| Federal excepted-benefit rule fails to finalize or is enjoined | Medium | High | The rule is proposed, not final, with an as-drafted January 1, 2027 effective date. Providers should not build 2027 capacity plans on it alone. State mandates are the more reliable near-term driver. |
| Embryo personhood spreads to additional states | Medium | Severe | Shield statutes are subordinate to state constitutional provisions. Multi-state operators should map exposure by jurisdiction and pre-plan embryo transport and storage contingencies. |
| Workforce shortage caps cycle growth | High | Medium to High | Structural and slow to fix given three-year REI fellowships and thin embryology pipelines. Task redistribution to advanced practice providers and OB-GYN upskilling programs are the practical levers. |
| Private-equity exit cycle reprices the sector | Medium to High | Medium | Multiple large platforms are simultaneously seeking exits. A weak first transaction sets a low benchmark and slows reinvestment across the sector. |
| Cost inflation outpaces coverage expansion | Medium | Medium to High | Surrogate compensation has risen roughly 36% over five years while surrogacy remains excluded from most mandates. Affordability, not supply, is already the binding constraint on surrogacy volume. |
| AI embryo-selection adverse outcome or regulatory clampdown | Low to Medium | Medium | Algorithmic transparency and data privacy concerns are already flagged in the literature. A high-profile failure would slow adoption of the sector's main efficiency lever. |
| Black swan: catastrophic multi-site cryostorage failure | Low | Extreme | A tank failure or systemic misidentification event at a major storage bank could trigger mass litigation, insurer withdrawal from the category, and emergency state regulation. ASRM has already flagged witnessing and misidentification as systemic risk points. This is the scenario that would reprice the entire sector overnight. |
Large networks and established suppliers should treat capacity, not demand generation, as the scarce resource. The firms that win the window will be those that solve throughput: recruiting and retaining embryologists, deploying automation that raises cycles per embryologist, and structuring OB-GYN partnerships that push diagnostic and IUI work upstream so that REI time is reserved for what only REIs can do.
Payer positioning is the second priority. With coverage shifting from self-pay to insured, named-network status with Progyny, Carrot, Maven, and Kindbody becomes a direct determinant of patient flow. Sector M&A commentary already identifies employer-benefit network status as a valuation driver alongside REI bench depth and above-average SART outcomes.
For platforms approaching sponsor exit, outcomes data is the asset. Success rates above the SART national average, modern accredited laboratories, and multi-state licensure across mandate states are what command a premium. Deferring lab modernization to protect near-term EBITDA is the predictable error.
Specialists should compete on legal certainty and segment depth rather than scale. In a period when Ukraine, Georgia, Russia, Argentina, and Greece have all tightened access and the Hague convention project has been suspended, an agency operating in a stable US jurisdiction sells predictability, and predictability is worth a premium to international intended parents who have watched pathways close mid-journey.
Transparency is an underused weapon. Circle Surrogacy publishes an all-inclusive figure; ConceiveAbilities and Growing Generations publish detailed compensation tiers. In a market where intended parents cite cost predictability among their primary buying criteria and where contingency line items are the main source of budget overrun, publishing a clear program structure converts a comparison-shopping visit into a consultation.
Finally, challengers should build for the benefit-funded intended parent. Employer plans administered through Progyny, Carrot, Maven, Kindbody, and WIN Fertility increasingly reimburse surrogacy-related costs, but reimbursement is milestone-tied and creates timing gaps against escrow schedules. An agency that can navigate a client's specific benefit plan, sequence milestones against reimbursement triggers, and document requirements correctly removes a real and growing source of friction that most competitors treat as the client's problem.
The buyer in third-party reproduction is a specific person: an intended parent aged roughly 30 to 50, financially stable enough to fund a six-figure journey, often a busy professional who values privacy and discretion, hopeful and determined but frequently arriving emotionally depleted by years of infertility. They may be part of a heterosexual couple, a same-sex couple, or building a family alone. What they are afraid of is concrete: legal complications, financial insecurity, and the possibility that a surrogate changes her mind. What they are looking for is a partner who is expert enough to handle the complexity and human enough to understand what it costs them.
That profile has direct implications for go-to-market.
The verdict for assisted reproductive technology and IVF from 2026 to 2031 is strong growth, with a base case of roughly $60 billion globally by 2031 against a $40 billion 2026 midpoint, an implied 8.4% CAGR consistent with the 8.28% Mordor Intelligence projects for IVF specifically. Demand is demographically locked in, coverage is expanding from both federal and state directions for the first time, and technology is improving throughput at the exact moment workforce constraints bind hardest.
The growth is not evenly distributed. Third-party reproduction, fertility preservation, and consumables outpace core clinical IVF. Asia-Pacific outpaces North America on volume while North America retains the revenue and legal-stability premium. And the sector carries a genuine tail risk that most healthcare categories do not: a legal question about the status of the embryo that no shield statute has fully resolved. CDC ART surveillance data show ART already accounts for about 2.6% of all US births, which means this is no longer a niche where legal disruption would be contained.
For operators in the third-party reproduction layer specifically, the window is favorable, but the terms are changing. Referral flow is being internalized by consolidated networks, buyers are better informed and more price-sensitive than they were five years ago, and legal certainty has become a product rather than a background assumption. The agencies that win will be the ones that acquire intended parents directly, price transparently, and can prove their jurisdictional stability.
